Clinical Trials Directory

Trials / Completed

CompletedNCT02335658

Long-term Study of DSP-5423P in Patients With Schizophrenia

Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Sumitomo Pharma Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.

Conditions

Interventions

TypeNameDescription
DRUGDSP-5423P40-80mg/day

Timeline

Start date
2014-12-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2015-01-12
Last updated
2022-04-12
Results posted
2020-11-19

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT02335658. Inclusion in this directory is not an endorsement.

Long-term Study of DSP-5423P in Patients With Schizophrenia (NCT02335658) · Clinical Trials Directory